CeNeRx Announces License Agreement with Krenitsky Pharmaceuticals Strategic partnership to by johnrr1

VIEWS: 48 PAGES: 1

									CeNeRx Announces License Agreement with Krenitsky Pharmaceuticals
Strategic partnership to develop and deliver medicines for the future
RESEARCH TRIANGLE PARK, NC, November 1, 2005 -- CeNeRx BioPharma, Inc., a start up biopharma-ceutical company focused on developing new therapeutics for disorders of the central nervous system, and Krenitsky Pharmaceuticals Inc. (KPI) today announced the licensing agreement of KPI's RIMA (reversible inhibitors of monoamine oxidase) antidepressant series. The RIMA series includes four pre-clinical/phase I antidepressants that are potentially safer versions of an older, but highly effective class of antidepressants known as monoamine oxidase inhibitors (MAOIs). Terms of the agreement grant an exclusive license to CeNeRx to fund the research and development trials (phase I and phase II) of the RIMA series before distributing the drug compound to a larger company for clinical trials (phase III). Undisclosed royalties will be made to KPI. “Antidepressant medications are widely used and are effective treatments for depression,” said Barry Brand, a former GlaxoSmithKline vice president and now CEO of CeNeRx. “Recent surveys indicate that one in ten Americans suffer from mood disorders at some point in their lives, thus validating the need for companies such as ours to develop and provide health care providers with new treatment options that are both safe and effective” Brand continued. “We are pleased to be partnering with CeNeRx BioPharma,” said Tom Krenitsky, CEO of Krenitsky Pharmaceuticals Inc. “They are uniquely suited to rapidly progress the RIMA series with their strong central nervous system development capability and solid antidepressant experience.” Unlike traditional classes of antidepressants, RIMA compounds are selective and reversible, meaning they work on all three neurotransmitters in the body, blocking degradation and ultimately increasing levels of neurotransmitters associated with mood, anxiety and somatic disorders. Animal studies conducted with the CeNeRx/KPI RIMA series show the desired elevation of key neurotransmitters is successfully reached at a lower dose level when compared to high doses of other RIMA-class antidepressants. The ability to achieve the necessary elevation of neurotransmitters with a lower drug dosage reduces the risk of a hypertensive crisis. Although RIMA antidepressants have been available in select European and international countries, this novel antidepressant class has yet to be introduced to the U.S. market.

About Krenitsky Pharmaceuticals, Inc. Krenitsky Pharmaceuticals, Inc. (KPI) is a privately held drug company in Durham, NC founded in 1995. KPI has a therapeutic focus on disorders of the nervous system and seeks to form partnerships with other companies for the clinical development, manufacturing and marketing of its products. KPI has an experienced team with a proven record of accomplishment in drug discovery and development. For more information visit www.kpi-pharma.com.


								
To top